Financial Health Snapshot
What does Bristol-Myers Squibb Company’s latest financial snapshot show?
Strong, but pressured. The strongest factor is cash generation, while the main concern is slower growth and pricing pressure.
Bristol-Myers Squibb Company’s latest verified period is Q1 2026, with annual context from FY2025. The verdict blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so it shows both the company’s scale and the near-term pressure on performance.
The latest revenue base was $1149B in Q1 2026, and gross margin was 703%, down 280 basis points, which shows strong profitability but some margin pressure. Q1 2026 EPS was $158, above consensus of $143 by 104%, and FY2025 total revenue was $482B. For a deeper read, revenue deserves first attention.
Revenue and Earnings Quality
Is Bristol-Myers Squibb Company turning revenue growth into quality earnings?
Mixed. The clearest confirmation is Q1 2026 Operating Income: $327B, which supports earnings quality, while revenue growth looks less durable because the year-over-year base is uneven and Eliquis concentration adds risk.
Growth quantity matters less than growth quality. Investors compare revenue durability with operating income, net income, and EPS across matching annual or quarterly periods to see whether sales convert into real profits, or whether pricing, mix, one-time items, or share count changes are masking weaker economics.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $1149B, 257% year-over-year, Q1 2026 | Company-reported prior-year quarter not supplied; FMP Revenue Growth: -810% | Organic growth; exact price-volume split unclear | Recurring specialty-medicine demand supports repeatability, but the growth base and external growth signals are inconsistent |
| Operating Income | $327B, Q1 2026 | Previous comparable value not supplied | Grew with revenue, but the exact pace is unavailable | Supports operating leverage and suggests sales are still flowing through to profit |
| Net Income | $268B, Q1 2026 | Previous comparable value not supplied | Operating result is supported, though interest, tax, or unusual items are not broken out here | Final earnings confirm profitability, but the full bridge to net income is not visible |
| Diluted EPS | $131, Q1 2026 | Previous comparable diluted EPS not supplied; FY2025 GAAP Diluted EPS: $346, Non-GAAP Diluted EPS: $615 | Per-share result depends partly on share count and period length | Shareholders saw positive per-share earnings, but quarterly and annual periods should not be compared directly |
How durable is Bristol-Myers Squibb Company revenue?
Durability looks moderate to strong. The best signal is recurring specialty-medicine demand across oncology, hematology, immunology, cardiovascular, and neuroscience. The biggest limitation is concentration, especially Eliquis Q1 revenue: $41B, plus mandatory US list price reductions that began January 01, 2026.
- Demand Quality: Demand is supported by recurring prescription use in major therapeutic areas, which is usually more visible than one-time sales.
- Pricing and Volume: Eliquis revenue rose 13%, but the exact split between price, volume, and mix is not provided.
- Diversification: Camzyos, Sotyktu, Cobenfy, Breyanzi, Opdualag, Reblozyl, and pipeline readouts help offset dependence, but they are not guaranteed replacement revenue.
That mix matters because stronger cash conversion usually follows when profit growth is steady and not overly dependent on one product.
Profitability and cash flow
Are BMY profitability and cash flow still strong?
Yes, BMY stayed profitable in Q1 2026, but cash conversion looked weaker. Gross margin fell 280 basis points, yet operating and net income remained positive. Operating cash flow was only $11B in Q1 2026 versus $142B in FY2025, and the negative free cash flow growth signal does not confirm earnings strength.
BMY’s income statement still shows profit at every level, with $807B gross profit, $327B operating income, and $268B net income in Q1 2026. But profitability quality is softer because cash flow lagged, while Bristol-Myers Squibb Company (BMY): History, Ownership, Mission, How It Works & Makes Money also faces margin pressure from Eliquis price reductions and the cost profile of a large pharma pipeline.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 703% in Q1 2026 | Unavailable in supplied data | Gross margin declined 280 basis points, and Eliquis price reductions of $12B pressured product economics. | Product economics weakened, so pricing pressure is still hurting profitability. |
| Operating Margin | Q1 2026 operating income of $327B | Unavailable in supplied data | FY2025 R&D expenses of $995B and SG&A expenses of $727B were down 11% and 14% under the $35B cost-cutting program. | Cost discipline helps, but scale efficiency is still being tested. |
| Net Margin | Q1 2026 net income of $268B | Unavailable in supplied data | Positive operating profit still flowed through to the bottom line, although Eliquis price reductions added pressure. | Final profitability is still positive, but it is not immune to pricing pressure. |
| Operating Cash Flow | $11B in Q1 2026 | $142B in FY2025 | Cash generation slowed sharply versus reported earnings, pointing to weaker latest-quarter conversion. | Earnings are not translating into the same level of cash. |
| Free Cash Flow | Unavailable; free cash flow value not supplied | Unavailable; free cash flow value not supplied | Free cash flow growth was -5281%, but no absolute free cash flow value was provided. | Reinvestment and financing capacity are harder to judge without the base number. |
What most affects BMY’s cash conversion?
The biggest driver is weaker cash conversion from lower operating cash flow, plus Eliquis price reductions and heavy R&D and SG&A spending. The cost cuts are structural, but the latest cash weakness looks more like a near-term pressure point.
- Main Driver: Lower operating cash flow versus earnings, with pricing pressure and investment spend weighing on conversion; the cost program is structural.
- Evidence Gap: The supplied data does not give free cash flow dollars or working-capital detail.
- Metric to Monitor: Track operating cash flow, free cash flow, and gross margin next quarter.
Balanced Leverage
Can Bristol-Myers Squibb Company’s balance sheet support its obligations and investment needs?
Mixed. Bristol-Myers Squibb Company has solid liquidity and debt-market access, but the main concern is heavy leverage against a patent-cliff period that can pressure cash flow and make refinancing or investment less flexible.
Cash by itself does not tell the full story. For Bristol-Myers Squibb Company, the key checks are working capital, asset quality, debt service, solvency, liquidity, and refinancing together, because a large cash balance can still sit beside heavy debt and intangible-heavy assets that may not protect investors in a downturn.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents: $957B, Short Term Investments: $91200M, Cash And Short Term Investments: $1049B, Net Receivables: $937B, Inventory: $276B, Total Current Assets: $2721B, 2026-03-31. | Mixed | Near-term obligations look manageable, but working capital still needs steady cash conversion to avoid strain on investment spending. |
| Total and Net Debt | Total Debt: $4446B at 2026-03-31, down from $4714B at 2025-12-31 and $5104B at 2025-09-30. | Mixed | Leverage is still high, so debt reduces flexibility even though the trend is moving the right way. |
| Debt Service and Refinancing | FY2025 net debt position was reduced by $44B, and Bristol-Myers Squibb Company completed a registered public offering of euro-denominated senior unsecured notes. | Strong | This shows access to debt markets and some refinancing support, which helps when patent pressure makes cash flow less predictable. |
| Asset Quality | Property Plant Equipment Net: $766B, Goodwill: $2174B, Intangible Assets: $1824B, Goodwill And Intangible Assets: $3998B, Total Assets: $8648B. | Mixed | Asset quality is mixed because a large share of assets is goodwill and intangibles, which are weaker buffers than cash or receivables. |
| Liabilities and Equity | Latest verified total liabilities and shareholders' equity were not supplied; market capitalization is not debt-paying capacity. | Mixed | The balance-sheet base is sizeable, but investors should focus on obligation coverage rather than market value. |
Which balance-sheet risk matters most for Bristol-Myers Squibb Company?
The biggest risk is leverage under patent-cliff pressure, because high debt can limit flexibility if operating cash flow weakens.
- Current Exposure: Total Debt: $4446B at 2026-03-31, with goodwill and intangible assets at $3998B.
- Protection: Cash And Short Term Investments: $1049B and reduced FY2025 net debt by $44B.
- Warning Signal: Watch cash flow, debt reduction, and working-capital movement if patent pressure starts to weigh on operations.
Capital Efficiency
Is Bristol-Myers Squibb Company reinvesting cash efficiently while funding growth?
Mixed. Bristol-Myers Squibb Company appears to fund reinvestment mostly from internal cash, but large R&D, dividend, and acquisition commitments still leave capital efficiency under pressure. The balance sheet does not look heavily strained from the facts provided, yet returns depend on disciplined pipeline execution and selective capital deployment.
Return quality should be judged alongside leverage, asset intensity, capital expenditure, working capital, and any need for outside funding. In a pharma model, strong cash generation can still coexist with uneven returns if R&D is heavy, acquisitions are frequent, or dividend commitments compete with pipeline spending and balance-sheet flexibility.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable | Operating margins and capital efficiency cannot be tested directly without a return figure. | Investors should treat value creation as unproven from the supplied data alone. |
| ROE and ROA | Unavailable | Leverage could lift ROE, while ROA would stay more sensitive to asset intensity. | Shareholder return quality cannot be judged cleanly without the missing return data. |
| Maintenance and Growth Investment | FY2025 Operating cash flow: $142B; Annual R&D Expenses: $995B; Q1 2026 Research And Development Expenses: $265B; $15B cash Orbital Therapeutics acquisition; AI research partnerships with Immunai, Tempus AI, Evinova, and Anthropic | R&D, selective M&A, and development productivity investments show active reinvestment, but the scale is best viewed as growth-oriented rather than maintenance-only. | Capital is being aimed at RNA medicine, in vivo CAR T capabilities, and faster discovery, not just sustaining current operations. |
| Internal Funding Capacity | FY2025 Operating cash flow: $142B; Annual R&D Expenses: $995B; Q1 2026 Research And Development Expenses: $265B; Weighted Average Shares Growth: 012%; Weighted Average Shares Diluted Growth: 012%; 17th consecutive annual dividend increase; 94th consecutive year of dividend payments | Operating cash flow suggests internal funding support, but dividends and acquisition spending compete with reinvestment, so funding is partly self-financed and partly constrained by capital return policy. | Internal cash appears important for growth funding, but shareholder payouts and deal spending reduce flexibility and can pressure future leverage or dilution if cash needs rise. |
Are Bristol-Myers Squibb Company’s returns on capital sustainable?
Likely mixed. The strongest durability source is internal cash generation, while the biggest risk is that heavy R&D, dividend commitments, and acquisition spending outpace pipeline productivity or force tighter funding choices.
- Operating Source: Cash generation supports reinvestment, and AI partnerships may improve development productivity.
- Funding Requirement: The largest verified needs are R&D spending, the $15B Orbital Therapeutics acquisition, and dividend outlays.
- Durability Test: Returns weaken if cash flow stops covering R&D and capital returns, or if share growth and balance-sheet strain rise.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help organize how Bristol-Myers Squibb Company balances growth spending and shareholder returns. Exploring Bristol-Myers Squibb Company (BMY) Investor Profile: Who's Buying and Why?
Financial Resilience
How resilient is Bristol-Myers Squibb Company, and which warning signs matter most?
Resilience is Mixed. The main buffer is a diversified specialty drug portfolio plus cost discipline and liquidity, but the most important verified warning sign is revenue replacement risk as Eliquis and Opdivo face major patent expirations between 2026 and 2028 that threaten about $15B in annual revenue.
Bristol-Myers Squibb Company can still protect debt service and essential investment, but the margin of safety is tighter than it looks. The company is leaning on the New Growth Portfolio target of $10B in incremental revenue by 2026, plus 10+ new medicines, 30+ new indications by 2030, and 10 potential data readouts scheduled for 2026. For readers using Mission Statement, Vision, & Core Values (2026) of Bristol-Myers Squibb Company (BMY), this is a useful place to connect strategy with financial resilience.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Patent expirations can reduce operating leverage, pressure earnings, weaken cash flow, and limit debt capacity if replacements lag. | New Growth Portfolio goals, high-margin specialty medicines, and cost discipline help offset the loss of mature products. | Watch for slower revenue replacement, weaker product mix, or continuing margin compression. |
| Working-Capital or Investment Pressure | Lower operating cash flow can leave less room for R&D, launch spending, and pipeline expansion without straining liquidity. | Internal funding capacity and liquidity support ongoing investment if cash conversion stays stable. | Monitor operating cash flow, cash conversion, and whether pipeline investment starts to crowd out flexibility. |
| Interest or Refinancing Pressure | Higher interest costs or refinancing needs would reduce free cash flow and narrow financing flexibility. | Net debt reduction and liquidity provide a partial cushion against funding stress. | Watch debt levels, maturity needs, and any rise in financing pressure or reduced liquidity access. |
Which financial warning signs should investors monitor at Bristol-Myers Squibb Company?
The top signals are revenue replacement progress, gross margin trend, and operating cash flow. Revenue and margin pressure are already visible, while weaker cash generation is a future risk if the pipeline does not offset patent losses fast enough.
Revenue Replacement Slips
Major patent expirations for Eliquis and Opdivo between 2026 and 2028 threaten about $15B in annual revenue. The main mitigant is the New Growth Portfolio, so track whether new launches and data readouts translate into actual sales.
Margin Compression From Eliquis Pricing
Mandatory US list price reductions for Eliquis began on January 01, 2026, and Q1 2026 impact from Eliquis price reductions was $12B. Gross Margin: 70.3% declined 280 basis points, so monitor whether cost discipline can hold margins steady.
Cash Conversion Weakens
Q1 2026 Operating Cash Flow: $1.1B was weaker than FY2025 Operating cash flow: $14.2B. Net debt reduction helps, but the key metric is whether operating cash flow recovers enough to fund R&D and launches without strain.
Financial Health Scorecard
How strong is Bristol-Myers Squibb Company financial health for investors?
Mixed overall. The strongest factor is cash generation, while the weakest is revenue durability. Bristol-Myers Squibb Company’s key financial condition is whether operating cash flow can stay strong enough to fund reinvestment, debt control, and the pipeline while legacy products face patent-cliff pressure.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | FY2025 Total Revenue: $482B and Q1 2026 earnings strength help, but modest growth and patent-cliff exposure limit durability and per-share visibility. |
| Profitability and Cash | Strong | Q1 2026 Gross Margin: 703%, Q1 2026 Net Income: $268B, and FY2025 Operating cash flow: $142B show strong cash generation despite margin compression. |
| Balance Sheet and Liquidity | Strong | Cash And Cash Equivalents: $957B, Cash And Short Term Investments: $1049B, and Add Total Debt: $4446B still leave flexibility and debt-service capacity. |
| Capital Efficiency | Mixed | Cash supports R&D and selective M&A, but pipeline replacement needs heavy reinvestment, so capital efficiency depends on successful new-product conversion. |
| Financial Resilience | Mixed | Strong cash and liquidity offset Eliquis pricing, Opdivo exposure, and patent-cliff risk, but resilience depends on keeping cash flow ahead of pressure. |
- What Supports the Thesis: Strong operating cash generation, ample liquidity, and lower debt create room for reinvestment and deleveraging; Exploring Bristol-Myers Squibb Company (BMY) Investor Profile: Who's Buying and Why? adds ownership context.
- What Challenges the Thesis: The main uncertainty is whether new products can replace pressured legacy revenue before patent-cliff losses deepen.
- What to Monitor: Q1 2026 Operating Cash Flow trajectory, Gross Margin after Eliquis price reductions, and Total Debt versus Cash And Cash Equivalents.
That mix matters because forecasts, scenarios, and valuation all depend on whether cash generation stays strong enough to absorb pipeline spending and revenue erosion.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
What Is BMY Operating Cash Flow Telling Investors?
FY2025 Operating cash flow: $142B shows strong annual cash generation, but Q1 2026 Operating Cash Flow: $11B and Operating Cash Flow Growth: -4407% show weaker latest-quarter conversion Investors should watch whether cash rebounds as pricing pressure and working-capital effects normalize
Why Does Gross Margin Matter For BMY Health?
Gross margin shows how much revenue remains after product costs before R&D, SG&A, interest, and tax Q1 2026 Gross Margin: 703% remains high, but the decline of 280 basis points signals pressure from pricing, mix, or cost factors
How Much Debt Can Bristol-Myers Squibb Carry?
The available data show Add Total Debt: $4446B and Cash And Cash Equivalents: $957B at 2026-03-31, plus FY2025 net debt reduction of $44B Comfort depends on sustained operating cash flow, refinancing access, and revenue replacement during the patent cliff
Can BMY Self-Fund Research And Development?
BMY appears able to fund significant R&D internally based on FY2025 Operating cash flow: $142B and Annual R&D Expenses: $995B The key test is whether quarterly operating cash flow stays strong enough to support R&D, dividends, and selective acquisitions
What Shows BMY Liquidity Is Adequate?
Liquidity is supported by Cash And Cash Equivalents: $957B, Short Term Investments: $91200M, and Cash And Short Term Investments: $1049B at 2026-03-31 Investors should still compare liquidity with debt service, working-capital needs, and patent-cliff funding demands